AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) Director David Epstein bought 14,980 shares of AgomAb Therapeutics stock in a transaction on Friday, November 13th. The shares were acquired at an average cost of $5.92 per share, for a total transaction of $88,681.60. Following the completion of the acquisition, the director directly owned 54,980 shares in the company, valued at approximately $325,481.60. The trade was a 37.45% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
AgomAb Therapeutics Stock Performance
Shares of NASDAQ AGMB opened at $5.82 on Thursday. The firm has a 50 day moving average price of $9.02 and a two-hundred day moving average price of $11.63. AgomAb Therapeutics NV has a 52-week low of $5.50 and a 52-week high of $17.82.
Analysts Set New Price Targets
AGMB has been the subject of a number of recent research reports. Johnson Rice restated a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, October 21st. B. Riley Financial began coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price on the stock. Cantor Fitzgerald began coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating on the stock. HC Wainwright reiterated a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, October 21st. Finally, Piper Sandler started coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, AgomAb Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.
Get Our Latest Research Report on AGMB
About AgomAb Therapeutics
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-? receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.
Featured Articles
- Five stocks we like better than AgomAb Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
